Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469607 | 1.00 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C19PPARASMN1; SMN2 | |
| SCHEMBL4475763 | 0.97 | SMN1; SMN2 (0.39) | CYP1A2CYP3A4CYP2C19PPARASMN1; SMN2 | |
| SCHEMBL4475755 | 0.97 | SMN1; SMN2 (0.39) | CYP1A2CYP3A4CYP2C19PPARASMN1; SMN2 | |
| SCHEMBL4470782 | 0.91 | SMN1; SMN2 (0.43) | CYP1A2CYP2C19SMN1; SMN2NPSR1RAB9A | |
| SCHEMBL4470785 | 0.91 | SMN1; SMN2 (0.43) | CYP1A2CYP2C19SMN1; SMN2NPSR1RAB9A | |
| SCHEMBL4473544 | 0.89 | CYP1A2 (0.36) | CYP1A2CYP3A4CYP2C19SMN1; SMN2NPSR1 | |
| SCHEMBL4491288 | 0.87 | POLB (0.38) | CYP1A2CYP3A4CYP2C19SMN1; SMN2NPSR1 | |
| SCHEMBL4491294 | 0.87 | POLB (0.38) | CYP1A2CYP3A4CYP2C19SMN1; SMN2NPSR1 | |
| SCHEMBL4479317 | 0.86 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19SMN1; SMN2NPSR1 | |
| SCHEMBL4470471 | 0.85 | RAB9A (0.39) | SMN1; SMN2NPSR1RAB9AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | CYP1A2 936/4885CYP3A4 973/4885CYP2C19 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.